Building CAR T Cells Inside the Body: A New Frontier in Cancer Therapy
CAR T-cell therapy is one of the most powerful tools oncology has produced in decades — but its complexity and cost put it out of reach for most patients.
The conventional CAR T-cell process is a manufacturing feat. T-cells are extracted from a patient, shipped to a specialised facility, genetically reprogrammed to recognise tumour antigens, expanded into large numbers, and reinfused weeks later. The process can cost hundreds of thousands of dollars per patient and doesn’t work reliably against solid tumours, which account for the vast majority of cancer deaths.
Researchers have now demonstrated an in-vivo alternative. Using lipid nanoparticles to deliver CRISPR instructions directly to T-cells circulating in live mice, they converted them into functional CAR T-cells without ever removing them from the body. The approach showed efficacy across three cancer types, including a solid tumour model — historically the most resistant to immunotherapy. Critically, the in-vivo generated cells appeared less exhausted and maintained killing activity longer than their lab-manufactured counterparts.
Why staying inside the body might matter
The performance advantage isn’t just about convenience. T-cells that mature and activate within their natural biological context may behave differently from cells that undergo ex-vivo manipulation under artificial conditions. The immune signals, the local cytokine environment, the metabolic state — all of these differ between a lab flask and a living organism. That difference may explain why in-vivo created cells appear to fight harder for longer.
The lipid nanoparticle delivery system is a reassuring choice of vehicle: the same basic technology underpinned the mRNA COVID-19 vaccines and has already been proven safe and effective at scale in humans. That doesn’t make human CAR T trials imminent, but it does mean the delivery mechanism is not the unknown variable.
The solid tumour problem
CAR T therapies have transformed outcomes for certain blood cancers — leukaemia, lymphoma, multiple myeloma. But solid tumours remain largely untouched. They suppress infiltrating T-cells through a hostile microenvironment, starving them of nutrients and flooding them with inhibitory signals. Whether in-vivo created cells are more resilient to those conditions in human tumours remains entirely untested.
The study was conducted in mice, and the gap between murine and human immunology is wide. Off-target editing — CRISPR hitting unintended genomic sites — must be rigorously characterised before any clinical application. The timeline to human trials and whether the method scales in biological complexity are questions that remain, for now, unanswered.